论文部分内容阅读
许多肿瘤,如神经内分泌肿瘤、甲状腺癌、乳腺癌等能高表达生长抑素受体,从而为生长抑素及其类似物的治疗提供了靶点。生长抑素受体介导的肿瘤靶向治疗主要包括放射性核素治疗、放射导向手术治疗、细胞毒素治疗和溶瘤病毒治疗。目前,生长抑素受体介导的放射性核素治疗已应用于神经内分泌肿瘤,尤其在胃肠胰神经内分泌肿瘤的诊断和治疗中占据重要地位。另外,生长抑素受体介导的放射导向手术治疗、细胞毒素治疗和溶瘤病毒治疗的潜在价值也越来越引起研究者们的重视。本文通过查阅近五年来关于生长抑素受体介导的肿瘤靶向治疗的国内外文献,综述了生长抑素受体介导的肿瘤靶向治疗的最新研究进展。
Many tumors, such as neuroendocrine tumors, thyroid carcinomas and breast cancers, can highly express somatostatin receptors, thus providing a target for the treatment of somatostatin and its analogues. Somatostatin receptor-mediated tumor targeted therapies include radionuclide therapy, radiation-guided surgery, cytotoxic therapy and oncolytic virus therapy. Currently, somatostatin receptor-mediated radionuclide therapy has been applied to neuroendocrine tumors, especially in the diagnosis and treatment of gastrointestinal pancreatic neuroendocrine tumors. In addition, the potential value of somatostatin receptor-mediated radiation-guided surgical treatment, cytotoxic therapy and oncolytic virus treatment is attracting more and more researchers’ attention. This review summarizes the latest research progress of somatostatin receptor-mediated tumor targeting therapy by reviewing the domestic and foreign literature on somatostatin receptor-mediated tumor targeting therapy in recent five years.